Summary

APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032

Market Overview
APAC, MENA, and Africa Sickle Cell Anemia Market is anticipated to register a notable CAGR of 14.77% during the review period. Sickle Cell Anemia is a genetic disorder that primarily affects red blood cells. It is caused by a mutation in the HBB gene, leading to the production of abnormal hemoglobin, called hemoglobin S. This causes red blood cells to become rigid and sickle-shaped, which can obstruct blood flow and cause various health complications.
The growing government support and policies associated with sickle cell anemia, and increased prevalence of sickle cell anemia increases the demand for drug treatment are major factors driving the growth of the APAC, MENA, and Africa. However, the high cost of bone marrow transplants and the side effects associated with drug treatment are expected to restrain the growth of the market. Nevertheless, the government is forming partnerships with manufacturers to produce affordable sickle cell disease medications and advancements in treatment options, which is attributed to creating lucrative opportunities for the players operating in the APAC, MENA, and Africa market.
Market Segmentation
Based on end user, the APAC, MENA, and Africa sickle cell anemia market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2022, while the specialty clinics segment is projected to be the fastest-growing segment during the forecast period, 2023–2032.
Based on treatment, the APAC, MENA, and Africa Sickle Cell Anemia market has been segmented into pharmacotherapy, blood transfusion, bone marrow transplant, and gene therapy. The blood transfusion segment dominated the market in 2022, while the gene therapy segment is projected to be the fastest-growing segment during the forecast period, 2023–2032.
Based on region, the APAC, MENA, and Africa sickle cell anemia market has been segmented into Asia-Pacific, Middle East & North Africa, Africa. Asia-Pacific accounted for the largest market share in 2022 and is anticipated to reach USD 4,220.86 million by 2032, registering a CAGR of 16.31% during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 16.31% during the forecast period.
Major Players
The key players operating in the APAC, MENA, and Africa Sickle Cell Anemia market are Pfizer Inc, Cipla ltd., Novartis AG, Emmaus Medical, Inc, Zydus Group, Vertex Pharmaceuticals Incorporated, and Nestlé.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 16
2 MARKET INTRODUCTION 18
2.1 DEFINITION 18
2.2 SCOPE OF THE STUDY 18
2.3 RESEARCH OBJECTIVE 18
2.4 MARKET STRUCTURE 18
3 RESEARCH METHODOLOGY 19
3.1 OVERVIEW 19
3.2 DATA FLOW 22
3.2.1 DATA MINING PROCESS 22
3.3 PURCHASED DATABASE: 23
3.4 SECONDARY SOURCES: 24
3.4.1 SECONDARY RESEARCH DATA FLOW: 25
3.5 PRIMARY RESEARCH: 26
3.5.1 PRIMARY RESEARCH DATA FLOW: 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 29
3.6.1 REVENUE ANALYSIS APPROACH 29
3.7 DATA FORECASTING 30
3.7.1 DATA FORECASTING TECHNIQUE 30
3.8 DATA MODELING 31
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 31
3.8.2 DATA MODELING: 32
3.9 TEAMS AND ANALYST CONTRIBUTION 33
4 MARKET DYNAMICS 35
4.1 INTRODUCTION 35
4.2 DRIVERS 36
4.2.1 GROWING GOVERNMENT SUPPORT AND POLICIES ASSOCIATED WITH SICKLE CELL ANAEMIA 36
4.2.2 INCREASED PREVALENCE OF SICKLE CELL ANEMIA INCREASES THE DEMAND FOR DRUG TREATMENT 36
4.3 RESTRAINTS 37
4.3.1 HIGH COST OF BONE MARROW TRANSPLANT AND SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT 37
4.4 OPPORTUNITY 38
4.4.1 GOVERNMENT IS FORMING PARTNERSHIPS WITH MANUFACTURERS TO PRODUCE AFFORDABLE SICKLE CELL DISEASE MEDICATIONS 38
4.4.2 ADVANCEMENTS IN TREATMENT OPTIONS 39
5 MARKET FACTOR ANALYSIS 40
5.1 PORTER'S FIVE FORCES MODEL 40
5.1.1 THREAT OF NEW ENTRANTS 40
5.1.2 BARGAINING POWER OF SUPPLIERS 41
5.1.3 THREAT OF SUBSTITUTES 41
5.1.4 BARGAINING POWER OF BUYERS 41
5.1.5 INTENSITY OF RIVALRY 41
5.2 IMPACT OF COVID-19 ON THE APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET 42
5.3 GLOBAL REVENUE OF MAJOR BRANDS 42
6 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY TREATMENT 43
6.1 INTRODUCTION 43
6.2 PHARMACOTHERAPY 45
6.3 BLOOD TRANSFUSION 45
6.4 BONE MARROW TRANSPLANT 45
6.5 GENE THERAPY 46
7 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY END USER 47
7.1 INTRODUCTION 47
7.2 HOSPITALS 49
7.3 SPECIALTY CLINICS 49
7.4 OTHERS 49
8 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY REGION 50
8.1 OVERVIEW 50
8.2 ASIA-PACIFIC 51
8.2.1 CHINA 53
8.2.2 INDIA 54
8.2.3 JAPAN 55
8.2.4 AUSTRALIA 55
8.2.5 SOUTH KOREA 56
8.2.6 REST OF ASIA-PACIFIC 57
8.3 MIDDLE EAST & NORTH AFRICA 58
8.3.1 UAE 61
8.3.2 EGYPT 61
8.3.3 SAUDI ARABIA 62
8.3.4 KUWAIT 63
8.3.5 QATAR 63
8.3.6 OMAN 64
8.3.7 IRAN 65
8.3.8 JORDAN 65
8.3.9 REST OF MENA 66
8.4 AFRICA 67
8.4.1 SOUTH AFRICA 69
8.4.2 ETHIOPIA 70
8.4.3 NIGERIA 70
8.4.4 REST OF AFRICA 71
9 COMPETITIVE LANDSCAPE 73
9.1 INTRODUCTION 73
9.2 MARKET SHARE ANALYSIS, 2022 73
9.3 COMPETITOR DASHBOARD 74
9.4 PUBLIC PLAYERS STOCK SUMMARY 75
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 75
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 76
9.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL 76
9.6.2 AGREEMENT 76
10 COMPANY PROFILES 77
10.1 PFIZER INC 77
10.1.1 COMPANY OVERVIEW 77
10.1.2 FINANCIAL OVERVIEW 78
10.1.3 PRODUCTS OFFERED 78
10.1.4 KEY DEVELOPMENTS 79
10.1.5 SWOT ANALYSIS 79
10.1.6 KEY STRATEGIES 80
10.2 EMMAUS MEDICAL, INC 81
10.2.1 COMPANY OVERVIEW 81
10.2.2 FINANCIAL OVERVIEW 82
10.2.3 PRODUCTS OFFERED 82
10.2.4 KEY DEVELOPMENTS 83
10.2.5 SWOT ANALYSIS 83
10.2.6 KEY STRATEGIES 84
10.3 NOVARTIS AG 85
10.3.1 COMPANY OVERVIEW 85
10.3.2 FINANCIAL OVERVIEW 86
10.3.3 PRODUCTS OFFERED 87
10.3.4 KEY DEVELOPMENTS 87
10.3.5 SWOT ANALYSIS 87
10.3.6 KEY STRATEGIES 88
10.4 CIPLA LTD 89
10.4.1 COMPANY OVERVIEW 89
10.4.2 FINANCIAL OVERVIEW 90
10.4.3 PRODUCTS OFFERED 90
10.4.4 KEY DEVELOPMENTS 90
10.4.5 SWOT ANALYSIS 91
10.4.6 KEY STRATEGIES 91
10.5 NESTLÉ 92
10.5.1 COMPANY OVERVIEW 92
10.5.2 FINANCIAL OVERVIEW 93
10.5.3 PRODUCTS OFFERED 93
10.5.4 KEY DEVELOPMENTS 94
10.5.5 KEY STRATEGIES 94
10.6 ZYDUS GROUP 95
10.6.1 COMPANY OVERVIEW 95
10.6.2 FINANCIAL OVERVIEW 96
10.6.3 PRODUCTS OFFERED 96
10.6.4 KEY DEVELOPMENTS 96
10.6.5 SWOT ANALYSIS 97
10.6.6 KEY STRATEGIES 97
10.7 SALIUS PHARMA PVT. LTD. 98
10.7.1 COMPANY OVERVIEW 98
10.7.2 FINANCIAL OVERVIEW 98
10.7.3 PRODUCTS OFFERED 98
10.7.4 KEY DEVELOPMENTS 99
10.7.5 KEY STRATEGIES 99
10.8 VERTEX PHARMACEUTICALS INCORPORATED 100
10.8.1 COMPANY OVERVIEW 100
10.8.2 FINANCIAL OVERVIEW 101
10.8.3 PRODUCTS OFFERED 101
10.8.4 KEY DEVELOPMENTS 101
10.8.5 SWOT ANALYSIS 102
10.8.6 KEY STRATEGIES 102
10.9 TAJ PHARMACEUTICALS LIMITED 103
10.9.1 COMPANY OVERVIEW 103
10.9.2 FINANCIAL OVERVIEW 103
10.9.3 PRODUCTS OFFERED 103
10.9.4 KEY DEVELOPMENTS 104
10.9.5 KEY STRATEGIES 104
10.10 CELON LABS 105
10.10.1 COMPANY OVERVIEW 105
10.10.2 FINANCIAL OVERVIEW 105
10.10.3 PRODUCTS OFFERED 105
10.10.4 KEY DEVELOPMENTS 106
10.10.5 KEY STRATEGIES 106